![](https://investorshub.advfn.com/uicon/33511.png?cb=1696427377)
Tuesday, November 26, 2013 5:34:32 PM
April 17th, 2013
http://seekingalpha.com/article/1347691-amarantus-lympro-could-be-a-game-changer-for-alzheimers-diagnosis
"Amarantus paid Memory Dx 2.0 million shares of common stock, and will pay a royalty equal to 9% of the net proceeds of all sales resulting from the license. Amarantus will fund the validation study for LymPro, and as has agreed to pay $50,000 to prepare the laboratory for the necessary CLIA work, which we expect to begin in the 3rd quarter of 2013. Memory Dx LLC is entitled to a $1.0 million milestone payment (in cash or stock) upon the successful completion of the phase II validation study, facilitating commercial sale of the product as an "aid to the diagnosis of Alzheimer's disease."
_________________________________________________________________________________________________________
you proclaim to be the single most biggest AMBS shareholder, and yet you don't know this fact ???
Whew..........
FEATURED ELEMENT79 GOLD CORP PROVIDES UPDATE ON CHACHAS COMMUNITY CHARTER AND REVENUE GENERATION, M&A ACTIVITIES • Jul 30, 2024 8:00 AM
Avant Technologies Opens Equity Line with GHS Investments as Company Explores Expansion into Additional Technologies • AVAI • Jul 30, 2024 8:00 AM
INDEXR AI Merges With Moon Equity Holdings Corp. (MONI), Creating a Leading-edge Technology Company • MONI • Jul 29, 2024 9:59 AM
Cannabix Technologies to Deliver Innovative Breath Logix Alcohol Screening Device to Texas, USA • BLOZF • Jul 29, 2024 9:07 AM
BNCM AND DELEX UNVEIL POST-MERGER MANAGEMENT PLANS • BNCM • Jul 29, 2024 9:00 AM
Glidelogic Corp. Announces Revolutionary AI-Generated Content Copyright Protection Solution • GDLG • Jul 26, 2024 12:30 PM